RSV Vaccine

BIOLOGICAL9 trials

Conditions

HealthyPregnancyRSVRespiratory Syncytial Virus (RSV)Respiratory Syncytial VirusesRespiratory Tract DiseasesRespiratory Tract InfectionTdap - Tetanus, Diphtheria and Acellular Pertussis Vaccination

Phase 1

A Study to Evaluate the Single Vaccination of an Adenovirus Serotype 26 Pre-Fusion F (Ad26.preF) Based Respiratory Syncytial Virus (RSV) Vaccine in Japanese Adults Aged 60 Years and Older

CompletedNCT04354480

Janssen Pharmaceutical K.K.Healthy

Start: 2020-05-15End: 2021-01-20Updated: 2025-02-03

Phase 2

A Study of an Ad26.RSV.preF-based Regimen in the Prevention of Reverse Transcriptase Polymerase Chain Reaction (RT-PCR)-Confirmed Respiratory Syncytial Virus (RSV)-Mediated Lower Respiratory Tract Disease in Adults Aged 65 Years and Older

TerminatedNCT03982199

Janssen Vaccines & Prevention B.V.Respiratory Syncytial Viruses, Respiratory Tract Diseases

Start: 2019-08-01End: 2023-05-26Updated: 2025-05-25

A PHASE 2B PLACEBO-CONTROLLED, RANDOMIZED STUDY OF A RESPIRATORY SYNCYTIAL VIRUS (RSV) VACCINE IN PREGNANT WOMEN

CompletedNCT04032093

PfizerRespiratory Tract Infection

Start: 2019-08-07End: 2021-09-30Updated: 2022-10-18

A STUDY OF A RSV VACCINE WHEN GIVEN TOGETHER WITH TDAP IN HEALTHY NONPREGNANT WOMEN AGED BETWEEN 18 TO 49 YEARS

CompletedNCT04071158

PfizerRespiratory Tract Infection

Start: 2019-10-01End: 2019-12-11Updated: 2021-02-15

A Study to Evaluate a Range of Dose Levels of an Adenovirus Serotype 26 (Ad26.RSV.preF)-Based Vaccine in Older Adults

CompletedNCT04453202

Janssen Vaccines & Prevention B.V.Healthy

Start: 2020-07-16End: 2021-04-09Updated: 2025-05-25

Phase 4

Immunogenicity of RSV Vaccines in Residents of Long-Term Care Facilities (LTCF)

CompletedNCT06077149

University of RochesterRespiratory Syncytial Virus (RSV)

Start: 2023-11-07End: 2024-11-01Updated: 2025-10-27

Concurrent Versus Sequential Administration of Tdap and RSV Vaccines in Pregnancy

RecruitingNCT07097012

Canadian Immunization Research NetworkHealthy, Pregnancy, RSV +1

Start: 2025-10-16End: 2027-10-01Target: 60Updated: 2026-03-12

Unknown Phase

Randomised, double-blind, placebo-controlled study to evaluate the safety, tolerability, immunogenicity and shedding of live-attenuated RSV vaccine in healthy adults

Active, not recruitingNL-OMON47495

IntravaccRespiratory Syncytial Virus (RSV)

Start: 2018-05-24Target: 48Updated: 2024-02-28

RSV Vaccine Pregnancy Registry

RecruitingNCT06521944

CorEvitasRespiratory Syncytial Virus (RSV)

Start: 2024-06-28End: 2030-09-30Target: 2062Updated: 2024-07-26

Vaccines2025-08-011 citations

Immunogenicity and safety of different dose levels of Ad26.RSV.preF/RSV preF protein vaccine in adults aged 60 years and older: A randomized, double-blind, placebo-controlled, phase 2a study

Vaccine2024-09-133 citations

A Randomized, Double‐Blind, Placebo‐Controlled, Phase 1 Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Single Vaccination of Ad26.RSV.preF‐Based Regimen in Japanese Adults Aged 60 Years and Older

Influenza and Other Respiratory Viruses2024-06-018 citations

Long-term efficacy and immunogenicity of Ad26.RSV.preF-RSV preF protein vaccine (CYPRESS): a randomised, double-blind, placebo-controlled, phase 2b study.

2024-05-2418 citations

Efficacy and Safety of an Ad26.RSV.preF–RSV preF Protein Vaccine in Older Adults

New England Journal of Medicine2023-02-15136 citations

2321. Long-term immunogenicity of Ad26.RSV.preF/RSV preF protein vaccine against RSV in a phase 2b study by age and risk level

Open Forum Infectious Diseases2022-12-013 citations

Prefusion F Protein–Based Respiratory Syncytial Virus Immunization in Pregnancy

New England Journal of Medicine2022-04-27176 citations

A Randomized Phase 1/2 Study of a Respiratory Syncytial Virus Prefusion F Vaccine

The Journal of Infectious Diseases2021-12-1698 citations

Safety and Tolerability of an Ad26.RSV.preF-based Vaccine in a Phase 2b Study in Older Adults

Innovation in Aging2021-12-01

Phase 2b Study of an Ad26.RSV.preF Vaccine for Prevention of RSV-mediated Respiratory Tract Disease in Older Adults

Innovation in Aging2021-12-01

LB14. Efficacy and Immunogenicity of an Ad26.RSV.preF-based Vaccine in the Prevention of RT-PCR-confirmed RSV-mediated Lower Respiratory Tract Disease in Adults Aged ≥65 Years: A Randomized, Placebo-controlled, Phase 2b Study

Open Forum Infectious Diseases2021-11-0113 citations

Safety and Immunogenicity of a Respiratory Syncytial Virus Prefusion F Vaccine When Coadministered With a Tetanus, Diphtheria, and Acellular Pertussis Vaccine

The Journal of Infectious Diseases2021-10-1143 citations